BzATP triethylammonium salt is a prototypic P2X7 receptor agonist that exhibits 5 - 10 fold greater potency than ATP (EC50 = 0.7 μM in HEK 293 cells). Exhibits partial agonist activity at P2X1 (pEC50 = 8.7) and P2Y1 receptors and can be used as a photoaffinity label for ATPase.
Williams and Coleman (1982) Exploring the adenine nucleotide binding sites on mitochondrial F1-ATPase with a new photoaffinity probe, 3'-O-(4-Benzoyl)benzoyl adenosine 5'-triphosphate. J.Biol.Chem. 257 2834. Zhong et al (1998) Pharmacological and molecular characterization of P2X receptors in rat pelvic ganglion neurons. Br.J.Pharmacol. 125 771. Michel et al (2001) Serum constituents can effect 2'- & 3'-O-(4-benzoylbenzoyl)-ATP potency at P2X7 receptors. Br.J.Pharmacol. 132 1501.
See how others have used BzATP triethylammonium salt. Click on the entry to view the PubMed entry .
PMID: # 28669743 Caglayan, B. et al. 2017. Exp. Neurol. 296: 23-31.
PMID: # 22644907 Gehring, MP. et al. 2012. Purinergic signalling. 8: 729-39.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.